This data is for laboratory research purposes only. Not for human or animal consumption.
What is DSIP (Delta Sleep-Inducing Peptide)?
DSIP (Delta Sleep-Inducing Peptide), also studied under the developmental/compounding name emideltide, is a nonapeptide first isolated in 1974 from the cerebral venous blood of rabbits during induced slow-wave sleep. It has been investigated since the late 1970s and through the early 1990s as a potential modulator of sleep architecture, stress response, and neuroendocrine regulation in humans.
Mechanism of Action
DSIP's precise receptor target remains incompletely characterized; proposed mechanisms include modulation of GABAergic and opioidergic signaling, interaction with the hypothalamic-pituitary-adrenal (HPA) axis (attenuating ACTH/cortisol release), and effects on luteinizing hormone (LH) secretion. Early human polysomnography studies tested intravenous DSIP for its purported ability to promote delta (slow-wave) sleep, the deepest non-REM sleep stage.
Observed Clinical Results
- Double-blind RCT in chronic insomniacs (Bes et al., Neuropsychobiology, 1992; PMID 1299794; n=16): Intravenous DSIP (25 nmol/kg) produced higher polysomnography-measured sleep efficiency and shorter sleep latency versus placebo, but the authors concluded the effects were statistically weak, possibly confounded by an incidental placebo-group change, and that short-term DSIP treatment "is not likely to be of major therapeutic benefit" for chronic insomnia.
- Older, smaller human trials from the late 1970s–1980s (e.g., studies in healthy volunteers and insomniac cohorts) reported mixed findings on sleep onset, sleep continuity, and subjective sleep quality, but sample sizes were small (typically under 20 subjects) and results were inconsistent across studies.
Critical Research Gaps
Human evidence for DSIP is decades old, drawn from small trials (generally fewer than 20 subjects), and inconsistent across endpoints. No modern (post-2000), adequately powered randomized controlled trial of DSIP/emideltide in humans has been identified. This sparse and dated evidence base was central to the FDA Pharmacy Compounding Advisory Committee's July 24, 2026 vote — see Regulatory Status below.
Regulatory Status Update (as of 2026-08-25): On July 24, 2026, the FDA's Pharmacy Compounding Advisory Committee voted 7–6 (1 abstention) against recommending DSIP/emideltide for the Section 503A Bulk Drug Substances List — the only rejection among the seven peptides reviewed that week (BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon were all recommended for listing). Committee members citing the "no" vote pointed to exactly this thin, dated human data set. As of this update, the FDA has not issued any further formal rulemaking action on the panel's July 2026 recommendations for any of the seven peptides reviewed; DSIP/emideltide remains outside the 503A compounding pathway. This is a nonbinding advisory outcome for the six recommended peptides and a nonbinding rejection for DSIP — none of these compounds has been added to or excluded from the 503A Bulks List through completed rulemaking.